(Porter Novelli) Shire Limited, the global specialty biopharmaceutical company, announces VYVANSE is available in US pharmacies in three additional dosage strengths, bringing the total dosage strength number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg. The expanded VYVANSE dosing options allow physicians to individualize treatment for each patient. VYVANSE, which received FDA approval for the treatment of ADHD in children in 2007, also recently approved to treat ADHD in adults. »»»

(Society for Experimental Biology and Medicine) Researchers at Tulane University Medical Center in New Orleans have discovered that drug-efflux pumps, belonging to the ATP-binding cassette transporter family, are constitutively expressed on vascular endothelial cells. The study has crucial implications in the persistence of sub-endothelial HIV reservoirs and will be important to the development of future therapies. »»»

(Summa Health System) Leaders from Summa Health System's Institute for Professionalism Inquiry have released a new book, "Narrative in Health Care." The book delves into the practice of narrative medicine, which recognizes that the stories of patients and clinicians are at the heart of patient care. »»»